| Source | M.W. | 513.64 | CAS No. | 957054-30-7 | |
|---|---|---|---|---|---|
| Structural Info | |||||
| Formulation | Powder | ||||
| Reconstitution | Before reconstitution, we recommend a brief spin to drive down any material dislodged from the bottom of the tube. The compound is soluble in DMSO. Poorly Soluble in water. Dilution into protein-containing aqueous media is recommended. | ||||
| Stability | The powder is stable for at least 2 year if stored at -20 °C. The dissolved compound is stable for at least 1 month at 4 °C, but should be stored in aliquots at -20 °C for longer term. Protect from light. | ||||
| Purity | Greater than 99% as determined by LC/MS analysis. LC/MS and/or NMR data available upon request. | ||||
| Biological Activity | |||||
| Country of Origin | USA | ||||
Chemical Name: 2-(1H-Indazol-4-yl)-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-(4-morpholinyl)-thieno[3,2-
d]pyrimidine
GDC-0941 is a potent inhibitor of PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ with IC50 of 3 nM, 33 nM, 3 nM and 75 nM,
respectively. Administration of GDC-0941 in animals displays significant inhibitory effect against established human cancer
xenografts. It is currently in clinical trials. PI3K inhibitors have been used for differentiation of pluripotent stem cells.
Ref: Folkes AJ, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 51(18):5522-32, 2008
Touboul, et al. Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology, 51: 1754–1765, 2010